GSK2618960

GSK2618960 is a human monoclonal antibody (mAb) targeting IL-7Ra/CD127. GSK2618960 inhibits IL-7-induced STAT5 phosphorylation. GSK2618960 enhances CD4 T cell proliferation response and increases CD83, CD86, and CD209 expression in PBMCs. GSK2618960 can be used in Multiple sclerosis and Sjogren's syndrome research. Recommended isotype control: Human IgG1 kappa, Isotype Control.

12352203

Interleukin Related; STAT

Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

COVID-19-immunoregulation

Inflammation/Immunology

95.66

[GSK2618960]

(144.93 kDa)

[1]Ellis J, et al. Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol. 2019 Feb;85 (2) :304-315.|[2]Liao K, et al. Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study. PLoS One. 2021 Mar 23;16 (3) :e0249049.

Dry Ice

-80°C

http://file.medchemexpress.com/batch_PDF/HY-P991424/GSK2618960-SDS-MedChemExpress.pdf

Inhibitory Antibodies

No Development Reported

IL-7; STAT5